Efficacy of varenicline to prompt quit attempts in smokers not currently trying to quit

A randomized placebo-controlled trial

John R. Hughes, Stephen Israel Rennard, James R. Fingar, Sandy K. Talbot, Peter W. Callas, Karl O. Fagerstrom

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Introduction: Nicotine replacement therapy to aid smoking reduction increases the probability of a future quit attempt among smokers not currently planning to quit smoking. We tested whether varenicline, a partial nicotine agonist, would also increase future quit attempts. Methods: This randomized, placebo-controlled trial recruited 218 smokers who were interested in quitting but had no plans to quit in the next month. Participants used varenicline (2 mg/day) or placebo for 2-8 weeks plus received brief counseling on methods to reduce cigarettes/day. The primary measure was the incidence of a quit attempt within 6 months of study entry. Secondary measures were point prevalence abstinence, motivation to stop smoking, and reduction in cigarettes/day. Results: Varenicline increased the incidence of a quit attempt more than placebo at the Nebraska site (73% vs. 41%; p < .001) but not at the Vermont site (45% vs. 51%; p = .45). Varenicline increased most other measures of quit attempts, motivation and abstinence, independent of site. The beneficial effects of varenicline in quit attempts appeared to be mediated by greater reductions in cigarettes/day, dependence, craving, and cigarette satisfaction. Varenicline had a greater effect on quit attempts in less-dependent smokers, in minority smokers, and in those who had less prior cessation or reduction activity. Adverse events were minimal. Conclusions: Varenicline increased quit attempts in smokers who are not currently trying to quit at one of the two study sites and improved most all secondary outcomes independent of site. This appeared to be due to decreasing cigarettes/day and level of dependence.

Original languageEnglish (US)
Pages (from-to)955-964
Number of pages10
JournalNicotine and Tobacco Research
Volume13
Issue number10
DOIs
StatePublished - Oct 1 2011

Fingerprint

Randomized Controlled Trials
Placebos
Tobacco Products
Smoking
Nicotine
Motivation
Incidence
Varenicline
Counseling

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Efficacy of varenicline to prompt quit attempts in smokers not currently trying to quit : A randomized placebo-controlled trial. / Hughes, John R.; Rennard, Stephen Israel; Fingar, James R.; Talbot, Sandy K.; Callas, Peter W.; Fagerstrom, Karl O.

In: Nicotine and Tobacco Research, Vol. 13, No. 10, 01.10.2011, p. 955-964.

Research output: Contribution to journalArticle

Hughes, John R. ; Rennard, Stephen Israel ; Fingar, James R. ; Talbot, Sandy K. ; Callas, Peter W. ; Fagerstrom, Karl O. / Efficacy of varenicline to prompt quit attempts in smokers not currently trying to quit : A randomized placebo-controlled trial. In: Nicotine and Tobacco Research. 2011 ; Vol. 13, No. 10. pp. 955-964.
@article{00dddb1a6bf14446a3e59aceedfc809f,
title = "Efficacy of varenicline to prompt quit attempts in smokers not currently trying to quit: A randomized placebo-controlled trial",
abstract = "Introduction: Nicotine replacement therapy to aid smoking reduction increases the probability of a future quit attempt among smokers not currently planning to quit smoking. We tested whether varenicline, a partial nicotine agonist, would also increase future quit attempts. Methods: This randomized, placebo-controlled trial recruited 218 smokers who were interested in quitting but had no plans to quit in the next month. Participants used varenicline (2 mg/day) or placebo for 2-8 weeks plus received brief counseling on methods to reduce cigarettes/day. The primary measure was the incidence of a quit attempt within 6 months of study entry. Secondary measures were point prevalence abstinence, motivation to stop smoking, and reduction in cigarettes/day. Results: Varenicline increased the incidence of a quit attempt more than placebo at the Nebraska site (73{\%} vs. 41{\%}; p < .001) but not at the Vermont site (45{\%} vs. 51{\%}; p = .45). Varenicline increased most other measures of quit attempts, motivation and abstinence, independent of site. The beneficial effects of varenicline in quit attempts appeared to be mediated by greater reductions in cigarettes/day, dependence, craving, and cigarette satisfaction. Varenicline had a greater effect on quit attempts in less-dependent smokers, in minority smokers, and in those who had less prior cessation or reduction activity. Adverse events were minimal. Conclusions: Varenicline increased quit attempts in smokers who are not currently trying to quit at one of the two study sites and improved most all secondary outcomes independent of site. This appeared to be due to decreasing cigarettes/day and level of dependence.",
author = "Hughes, {John R.} and Rennard, {Stephen Israel} and Fingar, {James R.} and Talbot, {Sandy K.} and Callas, {Peter W.} and Fagerstrom, {Karl O.}",
year = "2011",
month = "10",
day = "1",
doi = "10.1093/ntr/ntr103",
language = "English (US)",
volume = "13",
pages = "955--964",
journal = "Nicotine and Tobacco Research",
issn = "1462-2203",
publisher = "Oxford University Press",
number = "10",

}

TY - JOUR

T1 - Efficacy of varenicline to prompt quit attempts in smokers not currently trying to quit

T2 - A randomized placebo-controlled trial

AU - Hughes, John R.

AU - Rennard, Stephen Israel

AU - Fingar, James R.

AU - Talbot, Sandy K.

AU - Callas, Peter W.

AU - Fagerstrom, Karl O.

PY - 2011/10/1

Y1 - 2011/10/1

N2 - Introduction: Nicotine replacement therapy to aid smoking reduction increases the probability of a future quit attempt among smokers not currently planning to quit smoking. We tested whether varenicline, a partial nicotine agonist, would also increase future quit attempts. Methods: This randomized, placebo-controlled trial recruited 218 smokers who were interested in quitting but had no plans to quit in the next month. Participants used varenicline (2 mg/day) or placebo for 2-8 weeks plus received brief counseling on methods to reduce cigarettes/day. The primary measure was the incidence of a quit attempt within 6 months of study entry. Secondary measures were point prevalence abstinence, motivation to stop smoking, and reduction in cigarettes/day. Results: Varenicline increased the incidence of a quit attempt more than placebo at the Nebraska site (73% vs. 41%; p < .001) but not at the Vermont site (45% vs. 51%; p = .45). Varenicline increased most other measures of quit attempts, motivation and abstinence, independent of site. The beneficial effects of varenicline in quit attempts appeared to be mediated by greater reductions in cigarettes/day, dependence, craving, and cigarette satisfaction. Varenicline had a greater effect on quit attempts in less-dependent smokers, in minority smokers, and in those who had less prior cessation or reduction activity. Adverse events were minimal. Conclusions: Varenicline increased quit attempts in smokers who are not currently trying to quit at one of the two study sites and improved most all secondary outcomes independent of site. This appeared to be due to decreasing cigarettes/day and level of dependence.

AB - Introduction: Nicotine replacement therapy to aid smoking reduction increases the probability of a future quit attempt among smokers not currently planning to quit smoking. We tested whether varenicline, a partial nicotine agonist, would also increase future quit attempts. Methods: This randomized, placebo-controlled trial recruited 218 smokers who were interested in quitting but had no plans to quit in the next month. Participants used varenicline (2 mg/day) or placebo for 2-8 weeks plus received brief counseling on methods to reduce cigarettes/day. The primary measure was the incidence of a quit attempt within 6 months of study entry. Secondary measures were point prevalence abstinence, motivation to stop smoking, and reduction in cigarettes/day. Results: Varenicline increased the incidence of a quit attempt more than placebo at the Nebraska site (73% vs. 41%; p < .001) but not at the Vermont site (45% vs. 51%; p = .45). Varenicline increased most other measures of quit attempts, motivation and abstinence, independent of site. The beneficial effects of varenicline in quit attempts appeared to be mediated by greater reductions in cigarettes/day, dependence, craving, and cigarette satisfaction. Varenicline had a greater effect on quit attempts in less-dependent smokers, in minority smokers, and in those who had less prior cessation or reduction activity. Adverse events were minimal. Conclusions: Varenicline increased quit attempts in smokers who are not currently trying to quit at one of the two study sites and improved most all secondary outcomes independent of site. This appeared to be due to decreasing cigarettes/day and level of dependence.

UR - http://www.scopus.com/inward/record.url?scp=80053490417&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053490417&partnerID=8YFLogxK

U2 - 10.1093/ntr/ntr103

DO - 10.1093/ntr/ntr103

M3 - Article

VL - 13

SP - 955

EP - 964

JO - Nicotine and Tobacco Research

JF - Nicotine and Tobacco Research

SN - 1462-2203

IS - 10

ER -